Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Teva
Express Scripts
Federal Trade Commission
Baxter
Boehringer Ingelheim
Daiichi Sankyo
Medtronic
Julphar
Cantor Fitzgerald
Accenture

Generated: February 21, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,889,185

« Back to Dashboard

Summary for Patent: 8,889,185
Title:Modified release compositions comprising tacrolimus
Abstract: A modified release composition comprising tacrolimus which is useful for the treatment or prevention of rejection reactions by transplantation of organs or tissues.
Inventor(s): Holm; Per (Vanlose, DK), Norling; Tomas (Lyngby, DK)
Assignee: Veloxis Pharmaceuticals A/S (Horsholm, DK)
Application Number:14/079,414
Patent Claim Types:
see list of patent claims
Use; Composition; Dosage form; Formulation;

Drugs Protected by US Patent 8,889,185

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Veloxis Pharms Inc ENVARSUS XR tacrolimus TABLET, EXTENDED RELEASE;ORAL 206406-001 Jul 10, 2015 RX Yes No ➤ Sign Up ➤ Sign Up PROPHYLAXIS OF ORGAN REJECTION ➤ Sign Up
Veloxis Pharms Inc ENVARSUS XR tacrolimus TABLET, EXTENDED RELEASE;ORAL 206406-002 Jul 10, 2015 RX Yes No ➤ Sign Up ➤ Sign Up PROPHYLAXIS OF ORGAN REJECTION ➤ Sign Up
Veloxis Pharms Inc ENVARSUS XR tacrolimus TABLET, EXTENDED RELEASE;ORAL 206406-003 Jul 10, 2015 RX Yes Yes ➤ Sign Up ➤ Sign Up PROPHYLAXIS OF ORGAN REJECTION ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 8,889,185

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Denmark2003 01232Aug 29, 2003
Denmark2003 01837Dec 11, 2003
Denmark2004 00079Jan 21, 2004
Denmark2004 00463Mar 23, 2004
Denmark2004 00467Mar 23, 2004

Non-Orange Book US Patents Family Members for Patent 8,889,185

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,994,214 Solid dispersions comprising tacrolimus ➤ Sign Up
8,591,946 Modified release compositions comprising tacrolimus ➤ Sign Up
9,161,907 Modified release compositions comprising tacrolimus ➤ Sign Up
8,617,599 Modified release compositions comprising tacrolimus ➤ Sign Up
8,623,411 Modified release compositions comprising tacrolimus ➤ Sign Up
9,757,362 Modified release compositions comprising tacrolimus ➤ Sign Up
8,889,186 Modified release compositions comprising tacrolimus ➤ Sign Up
8,623,410 Modified release compositions comprising tacrolimus ➤ Sign Up
8,486,993 Solid dispersions comprising tacrolimus ➤ Sign Up
8,586,084 Modified release compositions comprising tacrolimus ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,889,185

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Slovenia 1663217 ➤ Sign Up
Slovenia 1663216 ➤ Sign Up
Portugal 1663217 ➤ Sign Up
Portugal 1663216 ➤ Sign Up
Norway 337869 ➤ Sign Up
Norway 20061430 ➤ Sign Up
Norway 334986 ➤ Sign Up
Norway 20061429 ➤ Sign Up
Japan 2011251972 ➤ Sign Up
Japan 4996249 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
Argus Health
Harvard Business School
Chinese Patent Office
Cerilliant
Mallinckrodt
US Army
Cipla
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot